From GlobeNewswire: 2025-04-26 10:00:00

Protara Therapeutics announced positive results for TARA-002 in high-risk Non-Muscle Invasive Bladder Cancer patients. The therapy demonstrated a 100% complete response rate at any time and a 67% complete response rate at 12 months in BCG-Unresponsive patients. In BCG-Naïve patients, the complete response rate was 76% at any time and 43% at 12 months. Safety profile was favorable with no Grade 3 or greater adverse events reported. The company plans to present updated interim data by the end of 2025 and will host a conference call on April 28, 2025, to discuss the results.



Read more at GlobeNewswire: Protara Therapeutics Announces Positive Interim Results